Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2013

Accessibility of Retinal Cells to Different AAV Serotypes After Intravitreal Injection in Old Versus New World Primates

Maureen Neitz; Anita Hendrickson; Michael Lukason; Jay Neitz; Daniel Possin; Gelareh Abedi; Jing Huang; Abraham Scaria; Sam Wadsworth

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2733.

ARVO Annual Meeting Abstract June 2013

Interleukin-17 neutralization ameliorates retinal degeneration in Cx3cr1-/-/Ccl2-/-/Crb1rd8 mice

Daniel Ardeljan; Yujuan Wang; De Fen Shen; Mones Abu-Asab; Jingsheng Tuo; Chengrong Yu; Gary White; Sam Wadsworth; Abraham Scaria; Chi-Chao Chan

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1713.

ARVO Annual Meeting Abstract April 2010

Safety & Efficacy of Intravitreal Anti-VEGF Gene Delivery in Non-Human Primates for the Treatment of Ocular Neovascularization

A. Scaria; T. MacLachlan; M. Lukason; P. Pechan; E. DuFresne; L. Isenberger; G. Veres; I. K. Kim; W. Hauswirth; S. Wadsworth

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4751.

ARVO Annual Meeting Abstract April 2010

AAV-Mediated sFLT-1 Gene Therapy Ameliorates Retinal Lesions in Ccl2/cx3cr1 Deficient Mice

J. Tuo; J.-J. Pang; X. Cao; D. Shen; J. Zhang; A. Scaria; S. C. Wadsworth; P. Pechan; W. W. Hauswirth; C.-C. Chan

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4509.

ARVO Annual Meeting Abstract April 2009

An Anti-VEGF Gene Therapy for Neovascular Age-related Macular Degeneration - Efficacy and Safety Studies in Murine and Primate Models

J. W. Miller; T. Maclachlan; M. Lukason; C. Flaxel; S. Kiss; G. Veres; W. Hauswirth; I. K. Kim; S. Wadsworth; A. Scaria

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4298.

ARVO Annual Meeting Abstract May 2008

Minimal Effective Dosing of a Novel Recombinant Form of VEGF Soluble Receptor 1 (sFlt-1) Delivered via AAV Vector in Inhibiting Choroidal Neovascularization in a Murine Model

W. W. Hauswirth; R. Miller; J. Pang; V. Choido; A. Abraham; P. Pechan; H. Rubin; S. Wadsworth; Q. Li

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1375.

ARVO Annual Meeting Abstract May 2006

Novel Anti–VEGF Molecules for Inhibition of Angiogenesis in the Eye

P. Pechan; H. Rubin; M. Lukason; J. Ardinger; D. Woodcock; J. Jaworski; H. Qiu; W. Hauswirth; S. Wadsworth; A. Scaria

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):854.

ARVO Annual Meeting Abstract May 2006

A Novel Recombinant Form of VEGF Soluble Receptor 1 (sFlt–1) Delivered via AAV Vectors Effectively Inhibits Choroidal Neovascularization in a Murine Model

Q. Li; R. Miller; J. Pang; S. Boye; V. Choido; A. Scaria; P. Pechan; H. Rubin; S. Wadsworth; W. Hauswirth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):901.

ARVO Annual Meeting Abstract May 2006

Evaluation of a Novel Anti–Neovascular Agent Delivered by an AAV Vector in the Mouse ROP Model

J.J. Peterson; M. Lukason; A. Scaria; P. Pechan; R. Hillard; Q. Li; R. Miller; S. Boye; S. Wadsworth; W. Hauswirth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):3222.

ARVO Annual Meeting Abstract May 2004

Intraocular Gene Delivery of Soluble VEGF Receptors

P. Pechan; M. Lukason; H.L. Rubin; A. Scaria; S. Wadsworth

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3712.

Advertisement